# PDX Core

> **NIH NIH U54** · WASHINGTON UNIVERSITY · 2024 · $165,970

## Abstract

PDX CORE SUMMARY
The Patient Derived Xenograft (PDX) Core is the epicenter of the Washington University PDX Development and
Trial Center (WU-PDTC). It will be responsible for the development, organization, characterization, storage, and
dissemination of high quality pathogen free PDX models for research projects investigating anticancer agents,
within and outside of WU-PDTC. Leveraging prior success and streamlined and efficient infrastructure, the PDX
Core will continue PDX development with a focus on creation of high-value specimens from biologically
prioritized specimens (e.g. treatment resistant cases). The Human and Mouse Linked Evaluation of Tumors
(HAMLET) PDX Core at the Institute of Clinical and Translational Study (ICTS) and the Solid Tumor Tissue Bank
and Registry (STTBR) led by Drs. Li and Fields, respectively, have a proven record of success in generating
PDX models from a wide variety of cancers and in utilizing these models for drug testing. These synergistic
programs have generated >1,000 models from >15 solid tumors, including large cohorts of recalcitrant cases
(e.g. treatment resistant pancrcreatic and triple-negative breast cancer) and genomically similar (e.g. HER-2
amplified) solid tumors that have led to multiple clinical trials in the ETCTN. These existing models will become
part of the renewal WU-PDTC, where ~400 new PDX models will be developed and added to this collection. The
new PDX models will further enhance our capability to support ongoing projects and open new opportunities for
research in clinically prioritized cancer themes. Taking advantage of the strong proteogenomic capability within
the proposed WU-PDTC and WUSM, we will expand the characterization of these PDX models to include cutting-
edge genomics, transcriptomics, proteomics, and metabolomics. This will provide investigators with a more
comprehensive picture of the mutational profiles, the molecular signatures, clonal structures, and heterogeneities
of the models to help with cancer sub-typing and target selection. Besides research projects at WU-PDTC, PDX
models in the PDX Core collection will also be shared with other PDTCs and made broadly available to
authorized non-network investigators. Existing infrastructure copuled with the large clinical oncology program at
WU and exceptionally strong institutional support, including matching funds, will ensure that the goals of the WU-
PDTC PDX Core goals are achievable.

## Key facts

- **NIH application ID:** 10881784
- **Project number:** 5U54CA224083-06
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Ryan C Fields
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $165,970
- **Award type:** 5
- **Project period:** 2017-09-30 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10881784

## Citation

> US National Institutes of Health, RePORTER application 10881784, PDX Core (5U54CA224083-06). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10881784. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*